{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:23Z","timestamp":1753891103225,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This article describes a 6-year-old patient diagnosed with \u201csystemic mastocytosis with AML1::ETO+ AML\u201d, he experience refractory disease during the course of treatment and salvage treatment was ineffective. The patient was administered gemtuzumab-ozogamicin therapy, resulting in rapid remission.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1566805","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:41Z","timestamp":1744176221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Song","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v188.5","article-title":"The clinical and pathological panoply of systemic mastocytosis","volume":"188","author":"Radia","year":"2020","journal-title":"Br J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.001","article-title":"Involvement of a common progenitor cell in core binding factor acute myeloid leukemia associated with mastocytosis","volume":"36","author":"Cornet","year":"2012","journal-title":"Leuk Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.04.009","article-title":"Acute myeloid leukemia with t(8;21)(q22;q22.1)\/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes","volume":"108","author":"Xie","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12308-009-0023-2","article-title":"Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia","volume":"2","author":"Pullarkat","year":"2009","journal-title":"J Hematop"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012006","article-title":"A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00650-4","article-title":"Avapritinib in the treatment of systemic mastocytosis: an update","volume":"16","author":"Below","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.v187.4","article-title":"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in hematological Malignancies","volume":"187","author":"Weisberg","year":"2019","journal-title":"Br J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4360304","DOI":"10.1155\/crh\/4360304","article-title":"KIT V560D-mutated systemic mastocytosis associated with high-risk myelodysplastic syndrome: A unique case of systemic mastocytosis-associated hematologic neoplasm","volume":"2024","author":"Medawar","year":"2024","journal-title":"Case Rep Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1Q0YSXEAHNKK","article-title":"Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22)","volume":"140","author":"Johnson","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2064994","article-title":"Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT","volume":"63","author":"Xue","year":"2022","journal-title":"Leuk Lymph"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ajcp\/aqad187","article-title":"Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis","volume":"161","author":"Nwogbo","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"44","author":"Borate","year":"2016","journal-title":"Leuk Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000152","article-title":"A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis","volume":"3","author":"Gotlib","year":"2019","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2010.07.003","article-title":"Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells","volume":"23","author":"Valent","year":"2010","journal-title":"Best Pract Res Clin Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.09.008","article-title":"Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils","volume":"35","author":"Krauth","year":"2007","journal-title":"Exp Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia","volume":"30","author":"Alvarez-Twose","year":"2016","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41375-024-02182-1","article-title":"Allogeneic hematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonization and Guidelines Committee","volume":"38","author":"McLornan","year":"2024","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02186-x","article-title":"Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries","volume":"38","author":"Lubke","year":"2024","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1566805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:42Z","timestamp":1744176222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1566805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2025.1566805"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1566805","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"article-number":"1566805"}}